| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6346e806124d182ed20f69fb75057a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_536d1d794ee35aa0941f125da8f0593c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd50ca52145ab2f11b7ab39c0b154ad6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1703
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00 |
| filingDate |
2007-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c34d1e8364a6e8fefe4111f1a819d4ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f72ef9874d899a800e7f65fbbf62580 |
| publicationDate |
2007-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2007109857-A1 |
| titleOfInvention |
Agent for the treatment of hormone-dependent disorders and uses thereof |
| abstract |
The present invention relates to novel agents that are useful for treating hormone-dependent disorders. In particular, the present invention relates to A method of modulating a nuclear receptor in vivo comprising the step of administering to a subject in need thereof A nuclear receptor modulating agent comprising a compound or composition capable of altering the endogenous levels of HLS-5 or its activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2007364-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2007364-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8778633-B2 |
| priorityDate |
2006-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |